Target Name: CCNG1
NCBI ID: G900
Review Report on CCNG1 Target / Biomarker Content of Review Report on CCNG1 Target / Biomarker
CCNG1
Other Name(s): Cyclin G | cyclin G1 | CCNG1 variant 1 | CCNG | Cyclin-G | Cyclin G1, transcript variant 1 | Cyclin-G1 | cyclin-G | CCNG1_HUMAN

Understanding Cyclin G: Potential Drug Target and Biomarker for Cancer

Cyclin G (CCNG1) is a protein that is expressed in various tissues throughout the body. It plays a crucial role in cell division and growth, and is often associated with the regulation of cell cycle progression. Cyclin G is a potential drug target and has has been identified as a biomarker for various diseases, including cancer. In this article, we will explore the biology of Cyclin G and its potential as a drug target.

The Biology of Cyclin G

Cyclin G is a member of the T-cell kinase family, which includes proteins that play a critical role in the regulation of cell cycle progression. These proteins phosphate cyclin D1 (CDK1), which is a key regulator of the cell cycle. By Phospholating CDK1, Cyclin G helps to regulate the growth and division of cells.

One of the unique features of Cyclin G is its ability to interact with the transcription factor, p21.p53. This interaction allows Cyclin G to regulate the activity of p21.p53, which is a critical regulator of apoptosis (programmed cell death). By Regulating the activity of p21.p53, Cyclin G helps to ensure that cells are able to divide and grow in a controlled manner.

Cyclin G is also involved in the regulation of the G1 phase of the cell cycle. During this phase, cells prepare for cell division by producing and replicating their genetic material. Cyclin G helps to regulate the production of the protein, cyclin D2 (CDK2) , which is necessary for cell division.

Potential Drug Target

Cyclin G is a potential drug target because of its involvement in the regulation of cell cycle progression. Many drugs that are used to treat cancer work by inhibiting the activity of Cyclin G. For example, the drug, taxol, is a microtubule inhibitor that inhibits the activity of tubulin, which is a key component of microtubules. This inhibition of tubulin results in the G1 phase of the cell cycle being prolonged, which can lead to the inhibition of cell division.

Another drug that is used to treat cancer is, p53 inhibitors. These drugs work by inhibiting the activity of the transcription factor, p53. This inhibition results in the inhibition of apoptosis, which is the programmed cell death that occurs during the G2 phase of the cell cycle.

Cyclin G is also a potential biomarker for cancer, as its expression is often increased in cancer cells. This makes it an attractive target for cancer therapies that are designed to target the expression of Cyclin G.

Conclusion

In conclusion, Cyclin G is a protein that plays a critical role in the regulation of cell cycle progression. Its interaction with the transcription factor, p21.p53 and the regulation of the G1 phase of the cell cycle make it a potential drug target for cancer Its potential as a biomarker for cancer makes it an attractive target for therapies that are designed to target the expression of Cyclin G. Further research is needed to fully understand the role of Cyclin G in cell biology and its potential as a drug target.

Protein Name: Cyclin G1

Functions: May play a role in growth regulation. Is associated with G2/M phase arrest in response to DNA damage. May be an intermediate by which p53 mediates its role as an inhibitor of cellular proliferation (By similarity)

The "CCNG1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCNG1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB